FDA green lights LVAD pocket controller

Candace Stuart | | Cardiovascular Business | Heart Rhythm

The FDA has approved the HeartMate II Pocket Controller, which is designed to enhance ease and safety for users of the HeartMate II left ventricular assist device (LVAD) system.

According to Pleasanton, Calif.-based Thoratec, the next generation pocket controller is lighter, smaller and easier to use than its predecessors. Features include prioritized visual alarms, on-screen instructions and a backup battery. It fits within a front pocket.

Physician training at centers that perform implants is to begin now. Once trained, physicians will be able to offer the pocket controller to new patients as well as upgrades to patients with HeartMate II LVADs.

Candace Stuart, Contributor

Related Content

Johnson & Johnson gains CE mark approval for catheter capable of radiofrequency, PFA ablation
Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications
History made: Young child treated with new heart device for very first time
ACC offers practical approaches for arrhythmia monitoring after stroke
FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.